Naratriptan Pregnancy and Breastfeeding Warnings
Naratriptan is also known as: Amerge
Naratriptan Pregnancy Warnings
Naratriptan has been assigned to pregnancy category C by the FDA. Animal tests have reported developmental toxicity (embryolethality, fetal abnormalities, pup mortality, and offspring growth retardation), dose-related increases in embryonic death, and fetal structural variations (incomplete/irregular ossification of skull bones, sternebrae, and ribs). High doses in animals have been reported to have lead to fused sternebrae, increased incidences of embryonic death, and fetal variations (major blood vessel variations, supernumerary ribs, and incomplete skeletal ossification). Treatment in animals during late gestation and lactation has been reported to have lead to offspring behavioral impairment (tremors), and decreased offspring viability and growth. There are no controlled data in human pregnancy. Naratriptan should only be given during pregnancy when benefit outweighs risk.
Naratriptan Breastfeeding Warnings
There are no data on the excretion of naratriptan into human milk.
The manufacturer has reported that naratriptan related material is excreted in the milk of rats.
- Naratriptan use while Breastfeeding (in more detail)
- naratriptan Consumer Information
- Pregnancy Support Group
- FDA Pregnancy Categories
- Medicine use during Pregnancy
- Medicine use while Breastfeeding
- Safe Medications during Breastfeeding
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.